Molecure SA
WSE:MOC
Relative Value
The Relative Value of one MOC stock under the Base Case scenario is hidden PLN. Compared to the current market price of 14.64 PLN, Molecure SA is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
MOC Competitors Multiples
Molecure SA Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
PL |
M
|
Molecure SA
WSE:MOC
|
246.5m PLN | 179.2 | -14.2 | -8.2 | -7.7 | |
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
731.8B USD | 20.4 | 119.2 | 58.4 | 66.4 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 16.5 | 45.1 | 33.6 | 36.9 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
372.2B USD | 4.3 | 9.7 | 11.9 | 15.6 | ||
US |
Merck & Co Inc
NYSE:MRK
|
332.3B USD | 5.4 | 144.1 | 35.9 | 58.5 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
187.7B GBP | 5 | 37.6 | 174.5 | 278.3 | ||
CH |
Roche Holding AG
SIX:ROG
|
189B CHF | 3.2 | 16.4 | 9.3 | 11 | ||
CH |
Novartis AG
SIX:NOVN
|
182.7B CHF | 3.4 | 11.5 | 8.7 | 12.7 | ||
US |
Pfizer Inc
NYSE:PFE
|
162.3B USD | 2.9 | -525.3 | 12.7 | 20.6 |